Holen Sie sich die Stockscreener-App
11.39
0.04%
-0.0241
Ocular Therapeutix Inc Aktie (OCUL) Neueste Nachrichten
OCUL Stock Is Climbing Ahead Of Investor Day — What Is On The Agenda? - Stocktwits
Ocular Therapeutix (OCUL): Faster Path To Approval Comes With Rising Costs - finance.yahoo.com
Ocular Therapeutix (OCUL) COO sells shares to cover taxes - Stock Titan
Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences - GlobeNewswire
Ocular Therapeutix Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Ocular Therapeutix (NASDAQ: OCUL) holder to sell 1,099 shares - Stock Titan
This Insider Has Just Sold Shares In Ocular Therapeutix - webull.com
Ocular Therapeutix Inc. (OCUL) Peer Comparison – Compare with Others - Value Research
Ocular Therapeutix CDO Peter Kaiser sells $32,686 of OCUL shares By Investing.com - Investing.com Nigeria
Ocular Therapeutix CEO Dugel sells $233,159 in shares By Investing.com - Investing.com Nigeria
Ocular Therapeutix CSO Heier sells $35,530 in stock - Investing.com
Ocular Therapeutix CSO Sanjay Nayak sells $20,449 in shares By Investing.com - Investing.com Nigeria
Ocular Therapeutix CSO Sanjay Nayak sells $20,449 in shares - Investing.com
Ocular Therapeutix CDO Peter Kaiser sells $32,686 of OCUL shares - Investing.com
Ocular Therapeutix (NASDAQ: OCUL) exec share sale covers RSU tax withholding - Stock Titan
Ocular Therapeutix (NASDAQ: OCUL) officer to sell 1,897 shares - Stock Titan
Ocular Therapeutix (NASDAQ: OCUL) insider plans 21,649-share sale - stocktitan.net
Why Ocular Therapeutix (OCUL) Is Up 10.4% After Q2 Beat And AXPAXLI Phase 3 Timeline Update - finance.yahoo.com
META_TITLE_QUOTE - Yahoo Finance
Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL) - Yahoo Finance
Ocular (OCUL) EPS and Revenue: Profit Per Share Clears Its Benchmark in the Latest Session; Market Reaction: The Stock Ends Down 5.46% in the Available RecordPost-Announcement Reaction - vinanet.vn
Ocular (OCUL) Latest Quarter: The EPS Result Is Above Expectation in the Latest Session; Shares Move 6.54% Up on the DayAdjusted Earnings Analysis - vinanet.vn
Ocular Therapeutix (OCUL) Institutional Ownership 2026 - MarketBeat
Clear Street Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Why Is Ocular Therapeutix Stock Gaining Monday? - Sahm
OCUL Looks 134.8% Overvalued on GF Value™ - GuruFocus
OCUL Stock Climbs As FDA Clears Path For AXPAXLI NDA - StocksToTrade
OCUL Stock Climbs As FDA Path And Cash Runway De‑Risk Story - timothysykes.com
Ocular Therapeutix (NASDAQ:OCUL) Shares Gap UpShould You Buy? - MarketBeat
Why is Ocular Therapeutix stock rallying today? By Investing.com - Investing.com Canada
OCUL Looks 141.9% Overvalued on GF Value™ - GuruFocus
Ocular Therapeutix stock rises as rival’s wet AMD trial stumbles By Investing.com - Investing.com South Africa
Ocular Therapeutix stock rises as rival’s wet AMD trial stumbles - Investing.com
EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback – Retail Sees Ocular Therapeutics As A Better Buyout Candidate - Stocktwits
(OCUL) Volatility Zones as Tactical Triggers - Stock Traders Daily
Ocular Therapeutix (OCUL) Posts Wider Losses And Files Shelf Registration, Is It Still Undervalued? - Sahm
OCUL|Ocular Therapeutix Inc|Price:9.890|Chg%:-0.210 - TradingKey
Ocular Therapeutix (NASDAQ:OCUL) Raised to "Hold" at Zacks Research - MarketBeat
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
Ocular Therapeutix’s New Policy Leader Gets an 85,000-Share Option - Stock Titan
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Dimensional Fund Advisors LP Takes $5.49 Million Position in Ocular Therapeutix, Inc. $OCUL - MarketBeat
Janus Henderson Group PLC Has $581,000 Holdings in Ocular Therapeutix, Inc. $OCUL - MarketBeat
The debate of durability in nAMD - Endpoints News
Ocular Therapeutix, Inc. $OCUL Shares Acquired by The Manufacturers Life Insurance Company - MarketBeat
Ocular Therapeutix (OCUL) Holds Steady Near $9.24 as Key Resistance Looms at $9.70Institutional Buy Signals - vinanet.vn
Does Ocular Therapeutix (OCUL) Pairing Flat Revenue With a New Shelf Point to a Shifting Funding Strategy? - Sahm
Ocular Therapeutix (NASDAQ:OCUL) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Ocular Therapeutix (OCUL) and Arcus Biosciences (RCUS) - The Globe and Mail
Here's What Analysts Are Forecasting For Ocular Therapeutix, Inc. (NASDAQ:OCUL) After Its Second-Quarter Results - simplywall.st
Ocular Therapeutix: AXPAXLI Can Turn Retina Capacity Into A Commercial Moat (NASDAQ:OCUL) - Seeking Alpha
0.61%
3.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):